Pharmaceutical Stock Reactions to Price Constraint Threats and Firm-Level R&D Spending
This study uses the Clinton Administrations Health Security Act of 1993 as a natural experiment to show how threats of price constraints affect firm-level R&D spending.
Link
Available for purchase at: http://papers.nber.org/papers/w11229